Anti-CD20 therapy reduces lesion volume and activated microglia in rodent models of multiple sclerosis

Anti-CD20 therapy reduces lesion volume and activated microglia in rodent models of multiple sclerosis

Bibliographic Details
Main Authors:	Seneca, N, Campbell, S, Balazs, M, Leppert, D, Anthony, D
Format:	Conference item
Published:	2012

Similar Items

Anti-CD20 Therapy Reduces Microglial Activation and Lesion Volume in Focal Models of Pattern I and Pattern II Multiple Sclerosis
by: Leppert, D, et al.
Published: (2012)

Anti-CD20 therapy reduces microglial activation and lesion volume in focal models of pattern I and pattern II multiple sclerosis
by: Anthony, D, et al.
Published: (2012)

Anti-CD20 therapy down-regulates lesion formation and microglial activation in pattern I and pattern II rat models of multiple sclerosis
by: Anthony, D, et al.
Published: (2014)

Anti-CD20 inhibits T cell-mediated pathology and microgliosis in the rat brain.
by: Anthony, D, et al.
Published: (2014)

Profiling of microglia nodules in multiple sclerosis reveals propensity for lesion formation
by: Aletta M. R. van den Bosch, et al.
Published: (2024-02-01)

Multiple Sclerosis anti-CD20 (Ocrelizumab) therapy inducing hypogammaglobulinemia
by: Nora Abdul-Aziz, et al.
Published: (2023-12-01)

Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
by: Despoina Florou, et al.
Published: (2020-10-01)

Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
by: Jérôme de Sèze, et al.
Published: (2023-03-01)

Microglia in the context of multiple sclerosis
by: Xue Zhang, et al.
Published: (2023-06-01)

Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: Gene expression and protein profiles
by: Chloe C. Fong, et al.
Published: (2023-04-01)

Partial volume-aware assessment of multiple sclerosis lesions
by: Mário João Fartaria, et al.
Published: (2018-01-01)

CD11c+ B cells in relapsing–remitting multiple sclerosis and effects of anti‐CD20 therapy
by: Sahla El Mahdaoui, et al.
Published: (2024-04-01)

Corrigendum: Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: gene expression and protein profiles
by: Chloe C. Fong, et al.
Published: (2023-08-01)

miRNAs in Microglia: Important Players in Multiple Sclerosis Pathology
by: Alexander D. Walsh, et al.
Published: (2021-01-01)

T cells and microglia as drivers of multiple sclerosis pathology.
by: Friese, M, et al.
Published: (2007)

T cells and microglia as drivers of multiple sclerosis pathology
by: Friese, M, et al.
Published: (2007)

Retinal and Brain Microglia in Multiple Sclerosis and Neurodegeneration
by: Soyoung Choi, et al.
Published: (2021-06-01)

Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti‐CD20 therapy
by: Mie Waede, et al.
Published: (2024-10-01)

Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill
by: Jagannadha Avasarala
Published: (2017-10-01)

Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
by: Stefan Gingele, et al.
Published: (2018-12-01)

Oral fingolimod (FTY720) therapy reduces blood brain barrier breakdown, microglial activation, and leukocyte recruitment in a focal DTH model of multiple sclerosis
by: Anthony, D, et al.
Published: (2009)

Immunocytochemical characterisation of the immune reaction in the central nervous system in multiple sclerosis. Possible role for microglia in lesion growth.
by: Woodroofe, M, et al.
Published: (1986)

Inflammatory microglia correlate with impaired oligodendrocyte maturation in multiple sclerosis
by: J. Q. Alida Chen, et al.
Published: (2025-01-01)

The Benefits and Detriments of Macrophages/Microglia in Models of Multiple Sclerosis
by: Khalil S. Rawji, et al.
Published: (2013-01-01)

Dynamic Responses of Microglia in Animal Models of Multiple Sclerosis
by: Melanie J. Plastini, et al.
Published: (2020-08-01)

Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: Evidence for distinct mechanisms of lesion genesis?
by: Lee, M, et al.
Published: (1999)

Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis?
by: Lee, M, et al.
Published: (1999)

Role of CD20<sup>+</sup>T lymphocytes in the pathogenesis of multiple sclerosis
by: N. S. Glebezdina
Published: (2024-07-01)

Role of CD20+ T cells in multiple sclerosis: implications for treatment with ocrelizumab
by: Stefan Gingele, et al.
Published: (2020-01-01)

Dimethyl fumarate reduces inflammation in chronic active multiple sclerosis lesions
by: Zinger, Nicole, et al.
Published: (2023)

Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients
by: Anas Elgenidy, et al.
Published: (2024-04-01)

Quantifying brain tissue volume in multiple sclerosis with automated lesion segmentation and filling
by: Sergi Valverde, et al.
Published: (2015-01-01)

Repeated iv anti‐CD20 treatment in multiple sclerosis: Long‐term effects on peripheral immune cell subsets
by: Julia Feige, et al.
Published: (2024-02-01)

Role of microglia in the pathogenesis of multiple sclerosis and links to immunomodulatory therapy
by: P. Valiukevičius, et al.
Published: (2023-10-01)

Microglia and Astrocytes in Neuro-Aids, Alzheimers Disease, and Multiple Sclerosis
by: Alireza Minagar, et al.
Published: (2001-01-01)

Manipulating Macrophage/Microglia Polarization to Treat Glioblastoma or Multiple Sclerosis
by: Thomas Kuntzel, et al.
Published: (2022-02-01)

Cortical lesions impact cognitive decline in multiple sclerosis via volume loss of nonlesional cortex
by: Eva A. Krijnen, et al.
Published: (2025-01-01)

Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model.
by: Anthony, D, et al.
Published: (2014)

The Role of the New Anti-CD20 Monoclonal Antibodies in Active Relapsing – Remitting Multiple Sclerosis Treatment: Efficacy and Safety of ofatumumab
by: I. Jonušaitė, et al.
Published: (2024-03-01)

Clinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study
by: André Aires Fernandes, et al.
Published: (2025-01-01)